Normal view MARC view ISBD view

A case of neonatal diarrhoea caused by congenital glucose-galactose malabsorption. [electronic resource]

By:

Lee, W S

Contributor(s):

Producer: 20091116Description: 83-5 p. digitalISSN:

0300-5283

Subject(s):

In: The Medical journal of Malaysia vol. 64

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Case Reports; Journal Article

There are no comments on this title.

to post a comment.

Back to results

4341 A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients.
by Netterberg, Ida
4342 Stromal Cell PD-L1 Inhibits CD8
by O'Malley, Grace
4343 Immune Checkpoint Molecules, Personalized Immunotherapy, and Autoimmune Diabetes.
by Orabona, Ciriana
4344 The Prognostic Value of Immune Factors in the Tumor Microenvironment of Penile Squamous Cell Carcinoma.
by Ottenhof, Sarah Rosanne
4345 Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
by Drakes, Maureen L
4346 Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
by Emens, Leisha A
4347 The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis.
by Gu, Lihu
4348 Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series.
by LoPiccolo, Jaclyn
4349 Comparison of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration With Stylet Retracted Partially Versus Completely for Molecular Testing.
by Fernandez-Bussy, Sebastian
4350 Macrophage migration inhibitory factor-CD74 interaction regulates the expression of programmed cell death ligand 1 in melanoma cells.
by Imaoka, Masako
4351 Therapeutic Potential of Checkpoint Inhibitors in Refractory Plasmablastic Lymphoma.
by Damlaj, Moussab
4352 Triptolide reverses helper T cell inhibition and down-regulates IFN-γ induced PD-L1 expression in glioma cell lines.
by Zhang, Lei
4353 First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment.
by Velcheti, Vamsidhar
4354 Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer.
by Guo, Lei
4355 Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry.
by Huang, Yu-Kuan
4356 Extrinsic Upregulation of PD-L1 Induced by Pembrolizumab Combination Therapy in Patients with NSCLC with Low Tumor PD-L1 Expression.
by Kunimasa, Kei
4357 Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy.
by Hsieh, Min-Shu
4358 VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer.
by Zong, Liju
4359 Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study.
by Manson, Guillaume
4360 Prognostic Value of p16 Protein in Patients With Surgically Treated Non-small Cell Lung Cancer; Relationship With Ki-67 and PD-L1.
by Pezzuto, Aldo